Open access
Open access
Powered by Google Translator Translator

HIV

RCT: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half.

21 Jun, 2022 | 11:11h | UTC

News Release: In people with HIV, treating precancerous anal lesions cuts risk of anal cancer by more than half – National Institutes of Health

Original Study: Treatment of Anal High-Grade Squamous Intraepithelial Lesions to Prevent Anal Cancer – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


M-A: Benefits and risks of rapid initiation of antiretroviral therapy in patients with HIV.

21 Jun, 2022 | 10:41h | UTC

Benefits and Risks of Rapid Initiation of Antiretroviral Therapy: A Systematic Review and Meta-Analysis – Frontiers in Pharmacology

 


The global landscape of the burden of depressive symptoms/major depression in individuals living with HIV/AIDs and its effect on antiretroviral medication adherence.

10 Jun, 2022 | 10:31h | UTC

The Global Landscape of the Burden of Depressive Symptoms/Major Depression in Individuals Living With HIV/AIDs and Its Effect on Antiretroviral Medication Adherence: An Umbrella Review – Frontiers in Psychiatry

 


Combination anti-HIV antibody infusions suppress virus for prolonged period.

7 Jun, 2022 | 11:45h | UTC

News Release: Combination anti-HIV antibody infusions suppress virus for prolonged period – National Institutes of Health

Original Study: Combination anti-HIV antibodies provide sustained virological suppression – Nature

 

Commentaries on Twitter

 


Guidelines for the Kaposi Sarcoma.

6 Jun, 2022 | 11:20h | UTC

S1 Guidelines for the Kaposi Sarcoma – Journal of the German Society of Dermatology

 


Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations.

16 May, 2022 | 01:41h | UTC

Oral pre-exposure prophylaxis (PrEP) to prevent HIV: a systematic review and meta-analysis of clinical effectiveness, safety, adherence and risk compensation in all populations – BMJ Open

 


Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19.

13 May, 2022 | 11:28h | UTC

Clinical features of, and risk factors for, severe or fatal COVID-19 among people living with HIV admitted to hospital: analysis of data from the WHO Global Clinical Platform of COVID-19 – The Lancet HIV

Invited Commentary: A collision of pandemics: HIV and COVID-19 – The Lancet HIV

 

Commentaries on Twitter

 


Capsid inhibition with Lenacapavir in multidrug-resistant HIV-1 infection.

12 May, 2022 | 10:20h | UTC

Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection – New England Journal of Medicine (link to abstract – $ for full-text)

Commentary: Lenacapavir for HIV Infection in a Multidrug-Resistant Study Cohort – ContagionLive

 


M-A: Evaluation of HIV treatment outcomes with reduced frequency of clinical encounters and antiretroviral treatment refills.

12 May, 2022 | 08:04h | UTC

Evaluation of HIV treatment outcomes with reduced frequency of clinical encounters and antiretroviral treatment refills: A systematic review and meta-analysis – PLOS Medicine

 


Review: Hemophagocytic Lymphohistiocytosis in patients with HIV.

11 May, 2022 | 10:47h | UTC

A Review of Hemophagocytic Lymphohistiocytosis in Patients With HIV – Open Forum Infectious Diseases

 


M-A: Early neurodevelopment of HIV-exposed uninfected children in the era of antiretroviral therapy.

1 May, 2022 | 23:09h | UTC

Early neurodevelopment of HIV-exposed uninfected children in the era of antiretroviral therapy: a systematic review and meta-analysis – The Lancet Child & Adolescent Health

 


Week 96 results from a RCT: Efficacy and safety of dolutegravir or darunavir combined with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection.

22 Apr, 2022 | 09:21h | UTC

Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial – The Lancet HIV

Invited Commentary: Game-changing study of second-line HIV treatment – The Lancet HIV (free registration required)

Original Study: Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV – New England Journal of Medicine

 

Commentary on Twitter

 


[News release – not published yet] New guidelines from WHO recommend a simpler, safer treatment for cryptococcal disease in people living with HIV.

21 Apr, 2022 | 10:28h | UTC

New guidelines from WHO recommend a simpler, safer treatment for cryptococcal disease in people living with HIV – World Health Organization

Related Study: Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis – New England Journal of Medicine (link to abstract – $ for full-text)

 


A preliminary study showed prolonged viral suppression is feasible with anti-HIV-1 antibody therapy.

18 Apr, 2022 | 10:06h | UTC

Prolonged viral suppression with anti-HIV-1 antibody therapy – Nature

 

Commentary on Twitter

 


M-A: Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV.

13 Apr, 2022 | 10:18h | UTC

Adverse perinatal outcomes associated with protease inhibitor-based antiretroviral therapy in pregnant women living with HIV: A systematic review and meta-analysis – EClinicalMedicine

News Release: Protease inhibitors safer than thought for pregnant women with HIV – University of Oxford

 


RCT: For adults with HIV, a 4-days-on and 3-days-off treatment strategy is noninferior to standard treatment for maintaining viral suppression.

11 Apr, 2022 | 01:56h | UTC

A 4-days-on and 3-days-off maintenance treatment strategy for adults with HIV-1 (ANRS 170 QUATUOR): a randomised, open-label, multicentre, parallel, non-inferiority trial – The Lancet HIV (link to abstract – $ for full-text)

Commentary: Intermittent Treatment Strategy Is Effective for HIV – Consultant360

 

Commentaries on Twitter

 


RCT: Cabotegravir (intramuscular injections every 8 weeks) for the prevention of HIV-1 in women.

6 Apr, 2022 | 10:51h | UTC

Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial – The Lancet (link to abstract – $ for full-text)

Related:

FDA approves first injectable treatment for HIV pre-exposure prevention.

RCT: Injectable long-acting Cabotegravir for HIV prevention in cisgender men and transgender women.

 


Systematic Review: Symptom‐ and chest‐radiography screening for active pulmonary tuberculosis in HIV‐negative adults and adults with unknown HIV status.

28 Mar, 2022 | 08:54h | UTC

Symptom‐ and chest‐radiography screening for active pulmonary tuberculosis in HIV‐negative adults and adults with unknown HIV status – Cochrane Library

Summary: How accurate are asking about symptoms and doing a chest X-ray to screen for tuberculosis of the lungs among adults who are HIV-negative or with unknown HIV status? – Cochrane Library

 


First case of HIV cure in a woman after stem cell transplantation reported at CROI-2022.

28 Mar, 2022 | 08:46h | UTC

First case of HIV cure in a woman after stem cell transplantation reported at CROI-2022 – World Health Organization

 


M-A: Tuberculosis screening among HIV-positive inpatients.

25 Mar, 2022 | 08:35h | UTC

Tuberculosis screening among HIV-positive inpatients: a systematic review and individual participant data meta-analysis – The Lancet HIV

 

Commentary on Twitter

 


RCT: Single-dose Liposomal Amphotericin B treatment for Cryptococcal Meningitis.

24 Mar, 2022 | 09:56h | UTC

Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis – New England Journal of Medicine (link to abstract – $ for full-text)

 

Commentary on Twitter

 


Systematic Review: Point‐of‐care viral load tests to detect high HIV viral load in people living with HIV/AIDS attending health facilities.

14 Mar, 2022 | 01:19h | UTC

Point‐of‐care viral load tests to detect high HIV viral load in people living with HIV/AIDS attending health facilities – Cochrane Library

Summary: Point-of-care tests for detecting high viral load in people living with HIV attending healthcare facilities – Cochrane Library

 


M-A: Outcomes of people living with HIV after hospital discharge.

10 Mar, 2022 | 10:26h | UTC

Outcomes of people living with HIV after hospital discharge: a systematic review and meta-analysis – The Lancet HIV

 

Commentary on Twitter (thread – click for more)

 


The Lancet Series: Ageing with HIV.

7 Mar, 2022 | 00:35h | UTC

Homepage: Ageing with HIV

Editorials:

Ageing with HIV

Time to tackle late diagnosis

Series:

Delayed presentation of HIV among older individuals: a growing problem

How health systems can adapt to a population ageing with HIV and comorbid disease

Biological ageing with HIV infection: evaluating the geroscience hypothesis

Intersectionality of stigmas and health-related quality of life in people ageing with HIV in China, Europe, and Latin America

 


RCT: Efficacy and safety of switching to the 2-drug regimen Dolutegravir/Lamivudine vs. continuing a 3- or 4-Drug regimen for maintaining virologic suppression in adults living with HIV-1.

7 Mar, 2022 | 00:32h | UTC

Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With HIV-1: Week 48 Results From the Phase 3, Non-inferiority SALSA Randomized Trial – Clinical Infectious Diseases

 


Stay Updated in Your Specialty

No spam, just news.